Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00560235 · ClinicalTrials.gov registry record · Phase 1
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 138
- Enrollment target
NCT00560235: Completed Phase 1 study, sponsored by Pfizer.
NCT00560235 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 138 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (130% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00560235, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 138 participants
- Enrollment target
Study Summary
Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors
Primary Outcome
Percentage of participants with objective response based on assessment of confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target and non-target disease and no new lesions. PR was defined as ≥30% decrease under baseline of the sum of diameters of all target lesions.
Interventions
- DRUG CP-751,871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
What the finished NCT00560235 record still lists
NCT00560235 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (130% higher).
The record links to 0 conditions, and to 1 intervention - of which CP-751,871 is the first listed.
NCT00560235 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00560235 about?
NCT00560235 is a clinical study titled "Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors". Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors
What is the current status of trial NCT00560235?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2008-03. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00560235?
The interventions under investigation include: CP-751,871 (DRUG).
Who is sponsoring clinical trial NCT00560235?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00560235's enrollment target sits among peer trials
138 418th of 2000 higher than 1,581 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia